Transgenomic Sees Q4 Revenues Decline, Negotiates $2.75M Convertible Note | GenomeWeb

NEW YORK, Feb. 24 (GenomeWeb News) - Transgenomic today reported a 7 percent drop in fourth-quarter revenues year over year, coupled with narrowed net losses, lower R&D spending, and dwindling cash reserves.

The company's revenues for the fourth quarter ended Dec. 31, 2003, were $8.5 million, down from $9.2 million in the year-ago period.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.